智通财经APP获悉，百心安-B(02185)尾盘涨超28%，截至发稿，涨25.71%，报4.84港元，成交额2726.37万港元。
消息面上，据报道，近日，美国医疗保险和医疗补助服务中心(CMS)发布新RDN医保提案。新提案建议将RDN纳入未控制高血压患者的医保覆盖范围。该提案已启动30天公众评议期，最终决定预计于2025年10月8日或之前公布。分析指出，此举有望推动RDN疗法普及，美敦力等医疗器械公司或将迎来增长机遇。
值得注意的是，今年2月，百心安附属上海安通医疗研发的Iberis多极肾动脉射频消融系统(IberisRDN系统)在德国完成首例商业化手术。6月3日，百心安公告称，Iberis多电极肾动脉射频消融RDN产品上市会于5月31日在第十九届东方心脏病学会议期间举行。据悉，Iberis RDN系统是全球唯一获批的可同时兼容经桡动脉入路和经股动脉入路的RDN产品。
更多港股重磅资讯，下载智通财经app
更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.